Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in Nijmegen – page 30

581 clinical trials in Nijmegen, The Netherlands across 7 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Nijmegen at a glance
581
clinical trials
  • Research sites7
Type of trial
Recruitment status
Quick filters

581 trials in Nijmegen

Open in trial search

Retinitis pigmentosa

Not recruiting

Study of ultevursen treatment in patients with retinitis pigmentosa caused by mutations in USH2A gene exon 13

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ultevursen
  • Sponsor:Laboratoires Thea

Study of alpelisib in children and adults with PIK3CA-Related Overgrowth Spectrum (PROS)

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Pertussis

Not recruiting

Study of acellular pertussis vaccine and its effect on whooping cough colonization in healthy adults using controlled human infection

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · Healthy volunteers
  • Substances:Azithromycin
  • Sponsor:Stichting Radboud universitair medisch centrum

Cholangiocarcinoma+7

Not recruiting

Study of bemarituzumab treatment for patients with solid tumors that have high levels of FGFR2b protein

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Pneumonia viral

Not recruiting

Study of inhaled interferon beta-1a (SNG001) for treatment of patients with viral lower respiratory tract infections who require mechanical ventilation

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Interferon BETA-1A
  • Sponsor:Synairgen Research Limited

Study of JSB462 and lutetium (177Lu) vipivotide tetraxetan combination for adult men with PSMA-positive metastatic castration resistant prostate cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide
  • Sponsor:Novartis Pharma AG

Arteriosclerosis

Not recruiting

Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Adenocarcinoma gastric+3

Not recruiting

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Migraine

Not recruiting

Study of Rimegepant for Prevention of Menstrual Migraine in Women Aged 18-45 Years

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Rimegepant
  • Sponsor:Pfizer Inc.

Study of ifinatamab deruxtecan alone or in combination with other treatments for patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Merck Sharp & Dohme LLC

Effectiveness and Safety of Rezafungin in Adults with Chronic Pulmonary Aspergillosis Who Have Limited Treatment Options

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Rezafungin Acetate
  • Sponsor:Mundipharma Research Limited

Colitis ulcerative

Not recruiting

Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Nijmegen

What the registry says about research in the country

01 Neurological Studies

Research focusing on various brain conditions, including glioblastoma imaging techniques and treatments for status epilepticus. Studies investigate brain tissue infiltration patterns and post-cardiac arrest neural conditions.

  • Brain tumor visualization
  • Serotonin's role in decision-making
  • Post-trauma stress disorders

Advanced imaging techniques and therapeutic interventions are being evaluated to improve patient outcomes.

02 Cardiovascular Research

Comprehensive studies examining heart failure prevention and treatment approaches. Investigations include new drug combinations and preventive strategies for cardiovascular events.

  • Heart failure prevention
  • Cardiovascular disease management
  • Post-cardiac arrest care

Clinical trials focus on both preventive measures and acute treatment protocols.

03 Cancer Studies

Innovative research in oncology, particularly focusing on advanced treatment approaches for various cancer types, including breast cancer and leukemia.

  • Breast cancer imaging
  • Leukemia treatments
  • Gastric cancer therapies

Studies evaluate new therapeutic combinations and diagnostic techniques.

04 Metabolic Disorders

Research examining gestational diabetes and obesity treatments, with emphasis on innovative imaging techniques and therapeutic approaches.

  • Diabetes management
  • Obesity treatments
  • Metabolic imaging

Focus on developing personalized treatment strategies.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.